SG11201405706TA - Treatment of cancer with tor kinase inhibitors - Google Patents

Treatment of cancer with tor kinase inhibitors

Info

Publication number
SG11201405706TA
SG11201405706TA SG11201405706TA SG11201405706TA SG11201405706TA SG 11201405706T A SG11201405706T A SG 11201405706TA SG 11201405706T A SG11201405706T A SG 11201405706TA SG 11201405706T A SG11201405706T A SG 11201405706TA SG 11201405706T A SG11201405706T A SG 11201405706TA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
kinase inhibitors
tor kinase
tor
Prior art date
Application number
SG11201405706TA
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of SG11201405706TA publication Critical patent/SG11201405706TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201405706TA 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors SG11201405706TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611370P 2012-03-15 2012-03-15
US201261715329P 2012-10-18 2012-10-18
PCT/US2013/031202 WO2013138556A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201405706TA true SG11201405706TA (en) 2014-10-30

Family

ID=47998542

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405706TA SG11201405706TA (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Country Status (21)

Country Link
US (1) US20130245029A1 (zh)
EP (1) EP2825168B1 (zh)
JP (2) JP2015516375A (zh)
KR (3) KR102057358B1 (zh)
CN (2) CN104302295B (zh)
AU (1) AU2013203156C1 (zh)
BR (1) BR112014022697A2 (zh)
CA (1) CA2867349A1 (zh)
EA (1) EA028434B1 (zh)
ES (1) ES2677908T3 (zh)
HK (1) HK1201755A1 (zh)
IL (2) IL234640B (zh)
MX (1) MX360877B (zh)
MY (1) MY182650A (zh)
NI (1) NI201400109A (zh)
NZ (1) NZ628421A (zh)
PH (2) PH12014502048A1 (zh)
SG (1) SG11201405706TA (zh)
TW (2) TWI664968B (zh)
WO (1) WO2013138556A1 (zh)
ZA (1) ZA201406709B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
NZ730189A (en) 2013-04-17 2018-09-28 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
AU2014254053B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with Dihydropyrazino-Pyrazines
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
SI3558997T1 (sl) * 2016-12-20 2021-07-30 Astrazeneca Ab Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
RU2757349C1 (ru) 2018-03-01 2021-10-13 Эссилор Энтернасьональ Элемент в виде линзы
CN113493471A (zh) * 2020-04-03 2021-10-12 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2381215T3 (es) * 2006-10-19 2012-05-24 Signal Pharmaceuticals Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
AU2007309468B2 (en) 2006-10-19 2012-05-17 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2011053518A1 (en) 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
KR102057358B1 (ko) 2019-12-18
EP2825168B1 (en) 2018-05-09
ZA201406709B (en) 2016-07-27
TW201733586A (zh) 2017-10-01
AU2013203156A1 (en) 2013-10-03
KR20190058673A (ko) 2019-05-29
EA028434B1 (ru) 2017-11-30
MX2014011117A (es) 2015-04-08
CA2867349A1 (en) 2013-09-19
NZ628421A (en) 2016-04-29
EP2825168A1 (en) 2015-01-21
PH12018502234A1 (en) 2019-08-14
EA201491694A1 (ru) 2015-06-30
ES2677908T3 (es) 2018-08-07
KR20200034818A (ko) 2020-03-31
CN104302295B (zh) 2017-06-20
HK1201755A1 (zh) 2015-09-11
CN107137402A (zh) 2017-09-08
AU2013203156B2 (en) 2015-12-10
PH12014502048B1 (en) 2014-12-10
IL234640B (en) 2020-05-31
TW201343167A (zh) 2013-11-01
US20130245029A1 (en) 2013-09-19
WO2013138556A1 (en) 2013-09-19
IL234640A0 (en) 2014-11-30
NI201400109A (es) 2015-01-15
PH12018502234B1 (en) 2019-08-14
TWI664968B (zh) 2019-07-11
PH12014502048A1 (en) 2014-12-10
JP2015516375A (ja) 2015-06-11
JP2018065820A (ja) 2018-04-26
MY182650A (en) 2021-01-27
AU2013203156C1 (en) 2016-02-18
MX360877B (es) 2018-11-21
JP6470821B2 (ja) 2019-02-13
TWI600428B (zh) 2017-10-01
IL274318A (en) 2020-06-30
BR112014022697A2 (pt) 2020-06-30
CN104302295A (zh) 2015-01-21
KR20140138929A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
HK1202247A1 (zh) 激酶抑制劑治療癌症
HK1201750A1 (zh) 使用 激酶抑制劑的癌症治療
HK1220640A1 (zh) 用谷氨醯胺酶的雜環抑制劑治療癌症
HK1201753A1 (zh) 使用 激酶抑制劑的癌症治療
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (zh) 癌症治療
HK1205500A1 (zh) 用於癌症治療的激酶抑制劑
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
GB201217890D0 (en) Treatment of cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
GB201208296D0 (en) Treatment of cancer